In patients with colorectal liver metastases, can we still rely on number to define treatment and outcome?

ONCOLOGY (United States)

Volumn 27, Issue 11, 2013, Pages

  Conrad, Claudius ^a   You, Y Nancy ^a   Vauthey, Jean Nicolas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; CANCER MORTALITY; COLON OBSTRUCTION; COLON PERFORATION; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; GENE MUTATION; HUMAN; LIVER RESECTION; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE COMPLICATION; TREATMENT OUTCOME;

EID: 84888390113     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Weiser MR, Jarnagin WR, Saltz LS. Colorectal cancer patients with oligometastatic liver disease: What is the optimal approach? Oncology (Williston Park). 2013; 27: 1074-8.
2. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003; 12: 165-92.
3. Blazer DG, 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008; 26: 5344-51.
4. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009; 302: 2338-44.
5. Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012; 30: 4566-72.
6. Kopetz S, Vauthey JN. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. Aug 2013. [Epub ahead of print].
7. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013; 258: 619-27.
8. Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009; 250: 540-8.
9. Hillingso JG, Wille-Jorgensen P. Staged or simultaneous resection of synchronous liver metastases from colorectal cancer-a systematic review. Colorectal Dis. 2009; 11: 3-10.
10. Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007; 14: 3481-91.
11. Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011; 29: 1083-90.
12. Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010; 210: 934-41.
13. Tzeng CW, Aloia TA, Vauthey JN, et al. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Ann Surg Oncol. 2013; 20: 482-90.
14. Cedermark B. Randomized study on preoperative radiotherapy in rectal carcinoma. Ann Surg Oncol. 1996; 3: 423-30.
15. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 1731-40.
16. Assumpcao L, Choti MA, Gleisner AL, et al. Patterns of recurrence following liver resection for colorectal metastases: effect of primary rectal tumor site. Arch Surg. 2008; 143: 743-9; discussion 49-50.
17. Chang CY, Kim HC, Park YS, et al. The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer. J Surg Oncol. 2012; 105: 244-8.
18. Chang G, Maru D, Agarwal A, et al. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. ESMO Congress Abstracts. 2010; 21: P-0032.
19. Cercek A, Weiser MR, Goodman KA, et al. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. ASCO Meeting Abstracts. 2010; 28: 3649.
20. http://www. cancernetwork. com/gastrointestinal-cancer.
21. http://www. cancernetwork. com/colorectal-cancer.
22. http://www. cancernetwork. com/oncology-journal.
23. http://www. cancernetwork. com/authors/claudius-conrad-md-phd.
24. http://www. cancernetwork. com/authors/y-nancy-you-md-mhsc.
25. http://www. cancernetwork. com/authors/jean-nicolas-vauthey-md.